Ee Lin joined HTANALYSTS in 2023, bringing more than 15 years of pharmaceutical industry experience and a background in clinical pharmacy. She specialises in market access and leads PBAC and MSAC submissions, as well as feasibility assessments across multiple therapeutic areas. In addition, she works on health economics and outcomes research, global value dossier development, and stakeholder engagement projects. Ee Lin is known for her analytical and quality-focused approach, supported by a strong risk management mindset. She has successfully led complex projects involving multiple stakeholders.

Before joining HTANALYSTS, Ee Lin held senior roles at Pfizer and AbbVie. During this time, she worked closely with cross-functional teams across medical, regulatory, commercial, and market access functions. As a result, she developed a strong understanding of product lifecycle management. Her pharmaceutical industry experience also provides valuable insight into the clinical, regulatory, and commercial factors that influence reimbursement and market access strategies.

Ee Lin is a registered pharmacist. She holds a Bachelor of Pharmacy (First Class Honours) from the University of Sydney and a Master of Public Health in Health Economic Evaluation from the University of New South Wales.